Categories Earnings, Health Care

AstraZeneca (NYSE: AZN): Q4 2019 Earnings Snapshot

— AstraZeneca (NYSE: AZN) reported fourth quarter 2019 earnings of $0.24 per share and core earnings of $0.89 per share.

— Revenue rose 8% to $6.66 billion vs. $6.75 billion expected. Products sales rose 8% year-over-year to $6.25 billion.

— Oncology sales advanced by 29% and respiratory sales grew by 13%. Biopharmaceuticals sales increased by 10% and new CVRM sales rose by 6% while sales in other medicines fell by 17%.

— Depending on the impact of the novel coronavirus (Covid-19) outbreak, AstraZeneca expects FY20 revenue to increase by a high single-digit to a low double-digit percentage and core EPS is expected to increase by a mid- to high-teens percentage.

— Guidance assumes an unfavourable impact from China lasting up to a few months as a result of the recent novel coronavirus (Covid-19) outbreak.

— AZN stock, which advanced 4% in the last three months, was down slightly during the before-market session.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

PG Earnings: Procter & Gamble Q3 profit climbs, beats estimates

Consumer goods behemoth The Procter & Gamble Company (NYSE: PG) announced financial results for the third quarter of 2024, reporting a double-digit growth in net profit. Sales rose modestly. Core

AXP Earnings: All you need to know about American Express’ Q1 2024 earnings results

American Express Company (NYSE: AXP) reported its first quarter 2024 earnings results today. Consolidated total revenues, net of interest expense, increased 11% year-over-year to $15.8 billion, driven mainly by higher

Netflix (NFLX) Q1 2024 profit tops expectations; adds 9.3Mln subscribers

Streaming giant Netflix, Inc. (NASDAQ: NFLX) Thursday reported a sharp increase in net profit for the first quarter of 2024. Revenues were up 15% year-over-year. Both numbers exceeded Wall Street's

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top